![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Switching from Efavirenz/Emtricitabine/Tenofovir DisoproxilFumarate(EFV/FTC/TDF) Single Tablet
Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir
DisoproxilFumarate(FTC/RPV/TDF) STR
in VirologicallySuppressed, HIV-1 Infected Subjects
|
|
|
Reported by Jules Levin EACS Belgrade Oct 12-15 2011
C Cohen,1A Mills,2E DeJesus,3B Rashbaum,4
C Brinson,5K Yale,6S Ramanathan,6H Wang,6
A Jandourek,6and A Cheng6
1Community Research Initiative, Boston, MA ; 2Anthony Mills MD Inc, Los Angeles, CA; 3Orlando Immunology Ctr, Orlando, FL; 4Capital Medical Associates, Washington, DC; 5Central Texas Clinical Research, Austin, TX; 6Gilead Sciencesnc., Foster City, CA
![EACS1.gif](../images/101711/101711-9/EACS1.gif)
![EACS2.gif](../images/101711/101711-9/EACS2.gif)
![EACS3.gif](../images/101711/101711-9/EACS3.gif)
![EACS4.gif](../images/101711/101711-9/EACS4.gif)
![EACS5.gif](../images/101711/101711-9/EACS5.gif)
![EACS6.gif](../images/101711/101711-9/EACS6.gif)
![EACS7.gif](../images/101711/101711-9/EACS7.gif)
![EACS8.gif](../images/101711/101711-9/EACS8.gif)
![EACS9.gif](../images/101711/101711-9/EACS9.gif)
![EACS10.gif](../images/101711/101711-9/EACS10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|